Document is current
Any future updates will be listed below
-
Authors
Nicolas, Philippe https://orcid.org/0000-0002-6527-3259
Marion-Moffet, Hugo
Gossez, Morgane
Vukusic, Sandra
Monneret, Guillaume
Marignier, Romain
Venet, Fabienne
-
Funding
Funding for this research was provided by:
Hospices Civils de Lyon
- License Information
-
More Information
Article History
Received: 15 July 2022
Revised: 21 August 2022
Accepted: 22 August 2022
First Online: 12 September 2022
Declarations
:
: S. Vukusic has received lecturing fees, travel grants, and research support from Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. P. Nicolas, H. Marion-Moffet, M. Gossez, G. Monneret, R. Marignier, and F. Venet report no disclosure relevant to the subject of this manuscript.
: This study is in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Patients were included in the French MS registry (OFSEP—Observatoire Français de la Sclérose en Plaques) and provided written informed consent, and healthy volunteers were included after informed consent as part of the REA-IMMUNO-COVID (RICO) clinical study (N°IRB/IORG #: IORG0009918; Agreement Number 2020-A01079-30; NCT04392401).
: This study is in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Free to read: This content has been made available to all.
